跳至主要内容
临床试验/CTRI/2019/06/019520
CTRI/2019/06/019520尚未招募4 期

Comparison of efficacy and safety of E.coli asparaginase against pegylated asparaginase in patients with childhood lymphoblastic leukemia: A population pharmacokinetic-pharmacodynamic approach

Dr Anand Srinivasan0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • a)Patients of 1-18 years of age undergoing induction phase chemotherapy for newly diagnosed acute lymphoblastic leukemia.
  • b)Patients whose parent/guardian are willing to give consent and children willing to give assent.

排除标准

  • a)Cases of ALL less than 1 year of age
  • b)Relapse cases of ALL
  • c)Prior history of hepatitis
  • d)Prior history of pancreatitis
  • e)Prior history of tuberculosis
  • f)Prior history of allergy to any of treatment medication used in the management of ALL.

研究者

发起方
Dr Anand Srinivasan

相似试验